Samsara Biocapital
Samsara Biocapital reported 27 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (31.7%), MLYS (14.0%) and SEPN (11.4%). Compared with Q2 2026, the fund opened new positions in PMVP, OBX and TCGX, added to ALMS, NGNE and VTVT, trimmed SEPN, AQST and AGMB and sold out of GOSS.
Latest filing: what Samsara Biocapital did in Q3 2026
vs Q2 2026
GOSS$1.2M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() SRRK Scholar Rock Hldg Corp | $333M | 31.7% | 6.9M | No change | 8 of 8 | |
| 2 | ![]() MLYS Mineralys Therapeutics Inc | $148M | 14.0% | 5.9M | No change | 8 of 8 | |
| 3 | ![]() SEPN Septerna Inc | $120M | 11.4% | 3.1M | −83K (−3%) | 8 of 8 | |
| 4 | ![]() ALMR Alamar Biosciences Inc | $84.5M | 8.0% | 2.5M | No change | 2 of 8 | |
| 5 | ![]() SGP Spyglass Pharma Inc | $54.9M | 5.2% | 2.1M | No change | 3 of 8 | |
| 6 | ![]() ALMS Alumis Inc | $53.5M | 5.1% | 7.2M | +891K (+14%) | 8 of 8 | |
| 7 | ![]() NGNE Neurogene Inc | $51.9M | 4.9% | 1.9M | +150K (+9%) | 8 of 8 | |
| 8 | ![]() KLRS Kalaris Therapeutics Inc | $37.2M | 3.5% | 12.9M | No change | 7 of 8 | |
| 9 | ![]() IVA Inventiva SA | $23.3M | 2.2% | 6.3M | No change | 4 of 8 | |
| 10 | ![]() PBLS Parabilis Medicines Inc Com | $18M | 1.7% | 556K | No change | 2 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() GOSS Gossamer Bio Inc | $1.2M | 7.2M |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Samsara Biocapital 13F FAQ
What does Samsara Biocapital own?
Samsara Biocapital reported 27 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (31.7%), MLYS (14.0%) and SEPN (11.4%). The table above lists every position in the filing (the top 10 without an account).
What did Samsara Biocapital buy and sell in Q3 2026?
Compared with Q2 2026: 4 new positions, 3 added to, 6 trimmed and 1 sold out. New positions include PMVP, OBX and TCGX. It sold all of GOSS.
When will Samsara Biocapital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Samsara Biocapital's portfolio worth?
The Q3 2026 filing reports $1.1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

















